Pheno Therapeutics

Doctor examining brain MRI
#Clinical trial #Multiple sclerosis #Neurology #Pheno Therapeutics

Pheno Therapeutics heads towards human testing of MS therapy

Biotechnology company Pheno Therapeutics has announced that the US Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for its lead therapeutic candidate PTD802 targeting multiple sclerosis (MS). The clearance follows a clinical trial authorisation (CTA) from the UK’s MHRA at the start… Read More

#News

Remyelination
#Acquisition #CNS #Drug discovery #Pheno Therapeutics #Phenomics #Phenotyping

Pheno Therapeutics buys rights to potential remyelination drug

Pheno Therapeutics has entered an agreement with UCB for the rights to develop, manufacture and commercialise a preclinical-stage programme of novel small molecules designed to promote remyelination.   “Pheno Therapeutics utilised its proprietary human phenotypic screening platform to discover novel and tractable therapeutic targets to modulate oligodendrocyte biology… Read More

#Business & Investment #News